Back

Samsung Biologics signs ₩350.8 billion CMO deal through 2033

Verifying
  • Samsung Biologics signed a CMO agreement with a European pharmaceutical company.
  • The contract is worth ₩350.8 billion ($262.18 million) and runs through 2033.
  • Samsung Biologics’ backlog reaches $21.9 billion after six contracts disclosed this year.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.